Published in BMJ Case Rep on May 09, 2013
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet (2004) 6.17
Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol (2011) 2.19
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol (2010) 1.72
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest (2011) 1.46
In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther (2006) 1.42
Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis (2009) 1.32
What is necessary to diagnose constipation? Best Pract Res Clin Gastroenterol (2011) 1.27
Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.19
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology (2012) 1.14
Colitis-induced alterations in adrenergic control of circular smooth muscle in vitro in rats. J Pharmacol Exp Ther (2001) 1.12
Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther (2007) 1.06
Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med (2012) 1.04
Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adv Exp Med Biol (2013) 0.98
Indacaterol: in chronic obstructive pulmonary disease. Drugs (2010) 0.96
Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology (2007) 0.88
Indacaterol: a novel long-acting β(2) -agonist. Pharmacotherapy (2012) 0.87
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr Med Res Opin (2009) 0.82
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12
Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. Pharmacoepidemiol Drug Saf (2011) 1.45
Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol (2011) 1.40
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology (2008) 1.20
Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf (2010) 1.10
Drug-induced liver injury: insights from genetic studies. Pharmacogenomics (2009) 1.10
HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology (2004) 1.09
Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf (2004) 1.07
Pharmacogenomics in drug induced liver injury. Curr Drug Metab (2009) 1.06
Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol (2008) 1.04
Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol (2002) 1.02
Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur Neuropsychopharmacol (2006) 0.96
Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol (2014) 0.95
Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Front Pharmacol (2012) 0.93
Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels. Antivir Ther (2006) 0.88
HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One (2013) 0.87
Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry (2002) 0.84
Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver Int (2013) 0.84
Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother (2004) 0.84
Hepatotoxicity related to citalopram. Am J Psychiatry (2004) 0.81
Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. Front Genet (2012) 0.81
Reflections on running training workshops for research ethics committee members in Spain between 2001 and 2008. Croat Med J (2010) 0.78
Epstein-Barr virus acute cholecystitis. BMJ Case Rep (2012) 0.77
Drug-induced hepatotoxicity. N Engl J Med (2003) 0.76
Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf (2007) 0.76
Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Rev Clin Pharmacol (2008) 0.76
Lansoprazole-induced hepatic dysfunction. Ann Pharmacother (2003) 0.76
Cholestatic hepatitis associated with repaglinide. Diabetes Care (2005) 0.76
Syndrome of inappropriate antidiuresis in doxylamine overdose. BMJ Case Rep (2012) 0.75
Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS One (2015) 0.75
Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs? World J Gastroenterol (2006) 0.75
Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles. Pharmacogenet Genomics (2016) 0.75
Drugs prescription in patients with chronic liver disease: rules for adjusting doses and beyond. Rev Esp Enferm Dig (2012) 0.75
Neisseria meningitidis cellulitis. Int J Infect Dis (2012) 0.75